中国医药：子公司天方药业阿司匹林肠溶片通过仿制药质量和疗效一致性评价

Core Viewpoint - The announcement indicates that Tianfang Pharmaceutical, a subsidiary of China Pharmaceutical, has received approval from the National Medical Products Administration for the supplement application of enteric-coated aspirin tablets, which have passed the consistency evaluation of generic drug quality and efficacy [1] Group 1: Product Approval and Market Potential - The enteric-coated aspirin tablets are primarily used for the treatment of unstable angina and acute myocardial infarction, with Bayer being the original manufacturer [1] - A total of 20 domestic companies have either passed or are deemed to have passed the consistency evaluation for this drug [1] Group 2: Sales Forecast - The estimated annual sales for this drug in domestic public hospitals and grassroots medical terminals is approximately 2.8 billion yuan for 2024 [1] - The projected sales for the first quarter of 2025 are around 800 million yuan [1]